Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.84B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 2.71M
Average 2.15M
COGT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cogent Biosciences, Inc.NASDAQ: COGT
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows in line with its trailing trend
Q2 FY2026 research & development of $70.81M rose 16.0% year over year, in line with the +15.9% change in trailing-twelve-month research & development. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +30.4% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +16.0% holds above the trailing-twelve-month pace of +15.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 269.78M USD
- Year-over-year change
- +16.0%
- 4-year CAGR
- +48.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 269.78M | +16.0% |
| FY2024 | 2024-12-31 | 232.66M | +33.9% |
| FY2023 | 2023-12-31 | 173.76M | +42.9% |
| FY2022 | 2022-12-31 | 121.63M | +117.5% |
| FY2021 | 2021-12-31 | 55.91M | — |
Research & Development vs competitors
How COGT compares with its peers on the latest reported figures
- COGT's LTM Jun 2026 research & development of $289.55M is the 5th highest of the 10 companies compared; the peer median is $260.36M.
- Its year-over-year change of +15.9% is the 3rd highest of 10, against a peer median of +9.1%.
- Over three fiscal years its annual growth of +30.4% compares with a peer median of +22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.15B | +9.1% | +8.9% | 37.0% | |
| LTM Jun 2026 | $497M | +2.5% | +22.0% | 424.8% | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Jun 2026 | $289.55M | +15.9% | +30.4% | — | |
| LTM Mar 2026 | $260.36M | +37.3% | +39.3% | 363.4% | |
| LTM Mar 2026 | $255.99M | +3.7% | +29.7% | 117.9% | |
| LTM Sep 2026 | $152.48M | +14.3% | +7.7% | — | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Mar 2026 | $114.57M | +28.4% | +7.1% | 572.9% | |
| Peer median (excluding COGT) | $260.36M | +9.1% | +22.0% | 150.7% | |
Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.62M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 55.91M | 121.63M | 173.76M | 232.66M | 269.78M |
| Selling, General & Admin | 19.64M | 26.21M | 34.38M | 43.28M | 63.58M |
| Operating Expenses | 75.55M | 147.84M | 208.13M | 275.94M | 328.74M |
| Depreciation & Amortization | 147K | 5.88M | 3.59M | 4.35M | 4.58M |
| EBITDA | (72.13M) | (130.37M) | (188.82M) | (251.51M) | (321.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (75.55M) | (147.84M) | (208.13M) | (275.94M) | (333.36M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 467K | 3.99M | 13.08M | 18.09M | 14.69M |
| Interest Expense | 0 | 3.99M | 0 | 0 | 3.06M |
| Other Income / Expenses | 3.28M | 7.6M | 15.72M | 20.08M | 4.43M |
| Income Before Tax | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| EPS (Diluted) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| Weighted Avg Shares | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
| Weighted Avg Shares (Diluted) | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.